markedly over the study period, with the highest rates being reported in 2010, the last year of collected data. This is in the setting of increasing use of primary PCI and decreasing use of fibrinolytic therapy in patients presenting with ST-segment elevation myocardial infarction (STE-MI). Although the rates of major adverse and cerebrovascular events were lower in all patients during this time period, those experiencing an MBE had worse short-and long-term outcomes than patients who did not have a bleeding episode.
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Although the overall rate of bleeding is low and likely reflects the specific bleeding definition utilized, the increasing rate of major bleeding over time described in this analysis is cause for concern, and stands in stark contrast to previous studies in large registries, none of which showed a significant increase in bleeding rates over time, despite the use of more robust antithrombotic strategies. Utilizing data from more than 1.7 million patients in the National Cardiovascular Data Registry's CathPCI Registry, Subherwal et al.
[2] described a 20% reduction in MBEs following PCI in [2005] [2006] [2007] [2008] [2009] . In their analysis, rates of bleeding reduction were similar among patients presenting with unstable angina/non-(N)STEMI from 2.3 to Bleeding is one of the most common complications among patients presenting with acute coronary syndrome (ACS) and is often precipitated by therapeutic intervention with potent antithrombotic medications and invasive procedures to restore perfusion to ischemic myocardium. Major bleeding is associated with short-and longterm morbidity and mortality, and bleeding related to percutaneous coronary intervention (PCI) is now tracked as a hospital quality indicator in the USA. As antithrombotic therapy has become more potent, there may be concern that with contemporary ACS management, the risk of bleeding is even higher now that it has been in the past.
In this issue of Cardiology , Sabbag et al.
[1] utilize a large Israeli registry of patients presenting with ACS in 2000-2010, to describe temporal trends of major bleeding and associated outcomes. Among the 11,538 patients enrolled in the study, 142 (1.2%) had a major bleeding event (MBE), defined as one of the following: a decrease in hemoglobin of 5 g/dl or a hematocrit drop of >15%, intracranial hemorrhage or retroperitoneal bleeding. Bleeding events were then further divided into access-site and nonaccess-site bleeding. Despite a modest decrease in bleeding events in 2000-2004, rates of bleeding increased 1.8% when compared to those with STEMI from 4.9 to 4.5%. Additionally, rates of access-site and non-access-site bleeding were similar in the unstable angina/ NSTEMI population, but significantly higher rates of non-access-site bleeding were observed in the STEMI population, presumably due to differences in procedural antithrombotic therapy. Fox et al.
[3] reported a similar reduction (from 2.6 to 1.8%) in MBEs (defined as lifethreatening bleeding occurring in hospital and resulting in a hematocrit decrease of ≥ 10%, transfusion of ≥ 2 units packed red blood cells and/or death due to subdural hematoma or hemorrhagic stroke) among 50,947 patients enrolled in the Global Registry of Acute Coronary Events (GRACE) Registry from 2000 to 2007. Similar increases in the rate of primary PCI and a reduction in the rate of fibrinolytic therapy were also observed in this population. In another analysis that combined non-ST-segment elevation ACS patients across 4 prospective multicenter registries, Elbarouni et al. [4] describe no significant increase in the rate of major bleeding (as defined by Fox et al. So what accounts for the disparity between the study by Sabbag et al. [1] and other published studies? One challenge in the study by Sabbag et al. [1] is the heterogeneity of the study population. Although the spectrum of ACS often shares a common pathophysiology, treatment pathways differ markedly, based on initial patient presentation, and the balance of benefit from early and rapid revascularization versus the risk of adverse events may shift in patients with unstable angina where immediate PCI is not the standard practice. In STEMI patients, timely and rapid reperfusion is the preferred treatment strategy, despite the potential increase in bleeding risk. Therefore, combining patients with non-ST-segment elevation ACS with STEMI may lead to results that are not necessarily reflective of actual rates of bleeding in the different categories of ACS. Indeed, the authors describe a significant reduction in the use of fibrinolytic therapy, from <50% in 2004 to <5% by 2010. A significant change in practice over a 6-year period can certainly influence the rate of bleeding; however, one would expect that a conversion from fibrinolysis to primary PCI would reduce bleeding, not increase it. Another reason for the increase could be the greater vigilance and reporting of bleeding complications. Recognition of the prognostic impact of bleeding in patients with ischemic heart disease was increasing between 2004 and 2010, and this may have influenced the reporting of major bleeding in the registry.
So is the incidence of bleeding in ACS patients increasing or decreasing? And does it really matter? The answer to the first question is probably 'both' -while the preponderance of evidence suggests that bleeding is likely decreasing, this may not apply to all ACS patients. Regional differences in antithrombotic therapy, dosing, the genetic response to antiplatelet drugs and the use of 'bleeding avoidance strategies' all influence the risk of bleeding complications. Ultimately, the second question may be more important. The results of Sabbag's analysis underscore the need for a focused effort to reduce the likelihood of MBEs in all patients using risk reduction strategies ( table 1 ) . Appropriate dosing and administration of antithrombotic therapies is essential, particularly with respect to more potent antiplatelet agents such as prasugrel which have demonstrated net harm in certain highrisk patients. Prior studies have noted incorrect dosing of anticoagulant therapies, particularly in high-risk populations [5] . Sabbag et al.
[1] note that among patients with bleeding events, one third developed either accesssite bleeding (25%) or retroperitoneal hematoma (8%), both of which could be significantly reduced with radialartery access, which was almost never used among the patients in their study. Multiple prior studies have demonstrated the benefit of transradial access with respect to access site complications and bleeding reduction. Among patients presenting with STEMI, the RIFLE-STEACS Trial showed reduced rates of the primary outcome of death/myo cardial infarction/stroke/target-vessel revascularization among patients undergoing transradial PCI (13.6 vs. 21.0%, p = 0.003) along with significant mortality (5.2 vs. 9.2%, p = 0.02) and bleeding reductions (7.8 vs. 12.2%, p = 0.026) [6] . More recently, the MATRIX Trial highlighted the superiority of the radial approach in patients presenting with ACS, with reductions in Bleeding Academic Research Consortium bleeding and all-cause mortality among those patients undergoing transradial access [7] . Previous studies, including the ACUITY [8] , HORIZONS-AMI [9] , and EUROMAX [10] Trials, have demonstrated reduced rates of major bleeding with bivalirudin in patients presenting with ACS and undergoing PCI, and bivalirudin use has been implemented as a bleeding avoidance strategy. However, more recent data from the HEAT-PPCI [11] have suggested that a periprocedural regimen of heparin only, in the setting of increased transradial use and more potent antiplatelet therapies, may have similar efficacy and bleeding. Although this is currently a topic of major debate, bivalirudin may play a role in bleeding reduction in high-risk patients, particularly those undergoing transfemoral PCI like those in the study by Sabbag et al. [1] . Finally, it should be noted that the data for bleeding reduction with vascular closure devices is mixed and may not support a significant role as part of a comprehensive bleeding reduction strategy. Sabbag et al.
[1] are to be commended for drawing attention to this concerning trend among patients in this registry. The most recent results demonstrating a continued increase in MBEs in Israel should serve as a focal point to develop a comprehensive strategy for bleeding reduction, incorporating procedural innovations as well as appropriate administration and dosing of anticoagulant and antiplatelet agents for ACS patients. Encouraging is the fact that major bleeding has decreased markedly worldwide from the earlier era of ACS management, suggesting that the increasing focus and attention to bleeding and the implementation of evidence-based strategies to avoid bleeding should reverse the trend of increased bleeding and worse short-and long-term outcomes observed in their study.
